Interferon ALPHA-2B

It is an antiviral or antineoplastic drug.

Interferon ALPHA-2B

INTERFERON ALFA-2B; C16H17Cl3I2N3NaO5S; SCHEMBL6041041

Intron-A, Realfa-2B, Shanferon, Viraferon

NA

NA

NA

Dose is based on patient’s condition. 

For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.

Hepatotoxicity, Flu-like symptoms; pneumonitis, pulmonary infiltrates and pneumonia, hypersensitivity reactions; alopecia; myelosuppression, nausea; ocular side effects; lethargy; autoimmune diseases, anorexia; CV problems; depression; nephrotoxicity; hypertriglyceridaemia; thyroid abnormalities; hyperglycaemia; psoriasiform rash; confusion; coma; seizures. 

• Reduces clearance of theophylline.
• Myelosuppression is enhanced with other myelosuppressive drugs (e.g. zidovudine).

Hypersensitivity. Hepatic decompensation, autoimmune hepatitis or a history of autoimmune disease, immunosuppressed transplant recipients.

Store at 2-8°C (36-46°F). 

Molecular weight

19271.0 Da

Molecular formula

C860H1353N229O255S9

CAS number

98530-12-2

Precautions

• History of pulmonary disease (e.g. COPD) or DM prone to ketoacidosis.
• Monitor patients with preexisting or history of psychiatric disorder, MI and/or arrhythmic disorders.
• Coagulation disorders or severe myelosuppression.
• Poorly controlled thyroid abnormalities.
• Perform ophthalmological exam on patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy).
• WBC count will be monitor in those receiving other myelosuppressive agents. and in myelosuppressed patients.
•  Preexisting psoriasis.
• Do not drive or operate machinery.
•  Pregnancy and lactation.